BioPharma Resources

Drug Trial Radar · NCT06966401

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

850

Planned (sponsor's estimate)

Start

Apr 16, 2025

Primary completion

May 2029

Study completion May 2030

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
May 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

Conditions

  • Major Depressive Disorder

Interventions

  • NBI-1065845Drug

    NBI-1065845 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline through Week 52

Locations

120 sites in 23 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Huntsville, Alabama · Recruiting

  • Neurocrine Clinical Site

    Bryant, Arkansas · Recruiting

  • Neurocrine Clinical Site

    Little Rock, Arkansas · Recruiting

  • Neurocrine Clinical Site

    Chino, California · Recruiting

  • Neurocrine Clinical Site

    Glendale, California · Recruiting

  • Neurocrine Clinical Site

    Irvine, California · Recruiting

  • Neurocrine Clinical Site

    Los Angeles, California · Recruiting

  • Neurocrine Clinical Site

    Oceanside, California · Recruiting

  • Neurocrine Clinical Site

    Orange, California · Recruiting

  • Neurocrine Clinical Site

    Pico Rivera, California · Recruiting

  • Neurocrine Clinical Site

    San Diego, California · Recruiting

  • Neurocrine Clinical Site

    San Francisco, California · Active not recruiting

  • Neurocrine Clinical Site

    San Jose, California · Recruiting

  • Neurocrine Clinical Site

    Upland, California · Terminated

  • Neurocrine Clinical Site

    Cromwell, Connecticut · Recruiting

  • Neurocrine Clinical Site

    Farmington, Connecticut · Recruiting

  • Neurocrine Clinical Site

    Hollywood, Florida · Recruiting

  • Neurocrine Clinical Site

    Maitland, Florida · Recruiting

  • Neurocrine Clinical Site

    Maitland, Florida · Recruiting

  • Neurocrine Clinical Site

    Miami, Florida · Recruiting

  • Neurocrine Clinical Site

    Miami Gardens, Florida · Recruiting

  • Neurocrine Clinical Site

    Orlando, Florida · Withdrawn

  • Neurocrine Clinical Site

    Palm Bay, Florida · Recruiting

  • Neurocrine Clinical Site

    Tampa, Florida · Recruiting

  • Neurocrine Clinical Site

    Tampa, Florida · Recruiting

  • Neurocrine Clinical Site

    Tampa, Florida · Recruiting

  • Neurocrine Clinical Site

    Atlanta, Georgia · Recruiting

  • Neurocrine Clinical Site

    Gaithersburg, Maryland · Recruiting

  • Neurocrine Clinical Site

    Boston, Massachusetts · Recruiting

  • Neurocrine Clinical Site

    Watertown, Massachusetts · Recruiting

  • Neurocrine Clinical Site

    O'Fallon, Missouri · Recruiting

  • Neurocrine Clinical Site

    Saint Charles, Missouri · Recruiting

  • Neurocrine Clinical Site

    Cedarhurst, New York · Recruiting

  • Neurocrine Clinical Site

    Mount Kisco, New York · Recruiting

  • Neurocrine Clinical Site

    New York, New York · Recruiting

  • Neurocrine Clinical Site

    New York, New York · Recruiting

  • Neurocrine Clinical Site

    The Bronx, New York · Recruiting

  • Neurocrine Clinical Site

    Avon Lake, Ohio · Recruiting

  • Neurocrine Clinical Site

    Edmond, Oklahoma · Recruiting

  • Neurocrine Clinical Site

    Oklahoma City, Oklahoma · Withdrawn

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.